[1] Polanczyk GV, Willcutt EG, Salum GA, et al. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis[J]. Epidemiol,2014,43(2):434-442.
[2] Bron T,Bijlenga D,Verduijn J. Prevalence of ADHD symptoms across clinical stages of major depressive disorder[J].J Affect Disord, 2016,197(1):29-35.
[3] Adamo N, Seth S, Coghill D. Pharmacological treatment of attention-deficit hyperactivity disorder: assessing outcomes[J]. Expert Rev Clin Pharmacol, 2015,8(4):383-397.
[4] VelöS, Keresztény A, Szentiványi D,et al. Quality of life of patients with attention-deficit/hyperactivity disorder: systematic review of the past 5 years[J]. Neuropsychopharmacol Hung, 2013,15(2):73-82.
[5] Montoya A, Quai D,Anand E,et al. Prognostic factors of improvement in health-related quality of life in atomoxetine-treated children and adolescents with attention deficit/hyperactivity disorder, based on a pooled analysis[J]. ADHD Atten Def Hyp Disord, 2014, 6(1):25-34.
[6] Coghill D,Banaschewski T,Soutullo C. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder[J]. Eur Child Adolesc Psychiatry,2017,26(11):1283-1307.
[7] Schei J, Novik TS, Thomsen PH, et al. Improved quality of life among adolescents with attention-deficit/hyperactivity disorder is mediated by protective factors: a cross sectional survey[J]. BMC Psychiatry, 2015, 15:108.
[8] Marques JC, Oliveira JA,Goulardins JB, et al. Comparison of child self-reports and parent proxy-reports on quality of life of children with attention deficit hyperactivity disorder[J]. Health Qual Life Outcomes, 2013, 11:186.
[9] Coghill D,Hodgkins P. Health-related quality of life of children with attention-deficit hyperactivity disorder versus children with diabetes and healthy controls[J]. Eur Child Adolesc Psychiatry,2016,25(3):261-271.
[10] Wehmeier PM, Schacht A, Dittmann RW, et al. Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder[J]. Qual Life Res, 2011, 20(5):691-702.
[11] Danckaerts M,Sonuga-Barke EJS,Banaschewski T,et al. The quality of life of children with attention deficit hyperactivity disorder:a systematic review[J]. Eur Child Adolesc Psychiatry, 2010,19(2):83-105.
[12] Banaschewski T, Johnson M, Lecendreux M, et al. Health-related quality of life and functional outcomes from a randomized withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder[J]. CNS Drugs, 2014,28(12):1191-1203.
[13] Dell′Agnello G, Maschietto D, Bravaccio C, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention deficit hyperactivity disorder and comorbid oppositional defiant disorder:a placebo-controlled Italian study[J]. Eur Neuropsychopharmacol, 2009,19(11):822-834
[14] CoghillD.The impact of medications on quality of life in attention-deficit hyperactivity[J]. CNS Drugs, 2010, 24 (10): 843-866.
[15] Berek M, Kordon A, Hargarter L, et al.. Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?[J]. Child Adolesc Psychiatry Men Health, 2011, 5:26.
[16] Hodgkins P, Shaw M, McCarthy S. The pharmacology and clinical outcomes of amphetamines to treat ADHD:does composition Matter?[J]. CNS Drugs, 2012, 26 (3): 245-268.
[17] Yang P, Hsu HY, Chiou SS, et al. Health-related quality of life in methylphenidate-treated children with attention deficit-hyperactivity disorder: results from a Taiwanese sample[J]. Aust NZJ Psychiatry,2007, 41(12):998-1004
[18] Wehmeier PM, Schacht A, Escobar R, et al.Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and attention deficit/hyperactivity disorder core symptoms: META-analysis of five atomoxetine trials[J]. Child Adolesc Psychiatry Ment Health, 2010, 4:30
[19] Savill NC,Buitelaar JK, Anand E,et al. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder:A comprehensive review of over a decade of clinical research[J]. CNS Drugs, 2015, 29(2):131-151.
[20] Escobar R,Schacht A,Wehmeier P, et al. Quality of life and attention deficit hyperactivity disorder core symptoms[J]. J Clin Psychopharmacol, 2010,30(2),145-151.
[21] Prasad S,Harpin V, Poole L, et al. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD)[J]. Curr Med Res Opin, 2007,23(2):379-394.
[22] Haynes H. Attention-deficit/hyperactivity disorder under treatment outcomes research (AUTOR): a European observational study in pediatric subjects ADHD[J].Atten Def Hyp Disord, 2015, 7(4):295-311.
[23] Cannon M, Pelham WH, Sallee FR, et al. Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder[J]. Child and Adolescent Psychopharmacology, 2009,19(5):511-517.